Table Graph
      published meta-analysis   sensitivity analysis   studies

azvudine in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsRen, 2020 1.00 [0.02; 55.80] 1.00[0.02; 55.80]Ren, 202010%20NAnot evaluable radiologic improvement (7-day)detailed resultsRen, 2020 19.00 [0.85; 422.73] 19.00[0.85; 422.73]Ren, 202010%20NAnot evaluable viral clearance detailed resultsOut of scaleRen, 2020 28.50 [1.27; 640.66] 28.50[1.27; 640.66]Ren, 202010%20NAnot evaluable viral clearance by day 7detailed resultsOut of scaleRen, 2020 28.50 [1.27; 640.66] 28.50[1.27; 640.66]Ren, 202010%20NAnot evaluable serious adverse eventsdetailed resultsRen, 2020 1.00 [0.02; 55.80] 1.00[0.02; 55.80]Ren, 202010%20NAnot evaluable adverse eventsdetailed resultsRen, 2020 0.12 [0.01; 2.86] 0.12[0.01; 2.86]Ren, 202010%20NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-04-28 12:34 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 537 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons